yingweiwo

Ciprofloxacin (Bay-09867)

Alias: Bay-09867; Baflox; Cetraxal; Ciprolin; Bay09867; Fimoflox; Bay 09867;Proflaxin; Spitacin
Cat No.:V1402 Purity: ≥98%
Ciprofloxacin (formerly known as Bay-09867;Bay09867;Baflox; Cetraxal; Ciprolin; Fimoflox; Proflaxin; Spitacin) is a broad-spectrum, fluoroquinolone class of antibiotic/antimicrobial which shows an MIC90 (minimal inhibitory concentrations for 90%) of between 0.008 and 2 μg/ml against various bacteria including Enterobacteriaceae, Haemophilus influenzae, Pseudomonas aeruginosa,Neisseria gonorrhoeae, Staphylococcus aureus,streptococci, and Bacteroidesfragilis strains.
Ciprofloxacin (Bay-09867)
Ciprofloxacin (Bay-09867) Chemical Structure CAS No.: 85721-33-1
Product category: Topoisomerase
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
2g
5g
10g
25g
Other Sizes

Other Forms of Ciprofloxacin (Bay-09867):

  • Ciprofloxacin HCl hydrate (Bay-09867)
  • Ciprofloxacin Hydrochloride (Bay-09867)
  • Ciprofloxacin lactate
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Ciprofloxacin (formerly known as Bay-09867; Bay09867; Baflox; Cetraxal; Ciprolin; Fimoflox; Proflaxin; Spitacin) is a broad-spectrum, fluoroquinolone class of antibiotic/antimicrobial which shows an MIC90 (minimal inhibitory concentrations for 90%) of between 0.008 and 2 μg/ml against various bacteria including Enterobacteriaceae, Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Staphylococcus aureus, streptococci, and Bacteroidesfragilis strains. Ciprofloxacin inhibits gyrase as a secondary target and topoisomerase IV as a primary target of topoisomerase.

Biological Activity I Assay Protocols (From Reference)
Targets
Topoisomerase IV
ln Vitro

Ciprofloxacin (Bay-09867) (5-50 μg/mL; 0-24 h; tendon cells) induces cell cycle arrest at the G2/M phase and suppresses cell proliferation[1].
Ciprofloxacin (Bay-09867) exhibits potent activity against Y. pestis and B. anthracis with MIC90 of 0.03 μg/mL and 0.12 μg/mL, respectively[2].

ln Vivo
Ciprofloxacin (Bay-09867) (30 mg/kg; i.p.; for 24 hours; BALB/c mice) provides protection against Y. pestis in murine model of pneumonic plague[3].
Ciprofloxacin (Bay-09867) (100 mg/kg; i.e., daily, for 4 weeks; C57BL/6J mice) increases the incidence of aortic dissection and rupture and accelerates the enlargement of the aortic root by decreasing the level of LOX and increasing the activity and levels of MMP in the aortic wall[4].
Ciprofloxacin (Bay-09867) (100 mg/kg; i.e., daily, for 4 weeks; C57BL/6J mice) causes mitochondrial dysfunction, cytosolic DNA sensor signaling activation, and DNA damage and release into the cytosol. Apoptosis and necroptosis in the aortic wall are increased by ciprofloxacin lactate[4].
Cell Assay
Cell Line: Tendon cells
Concentration: 5, 10, 20 and 50 μg/mL
Incubation Time: 24 hours
Result: Decreased the cellularity of tendon cells.
Animal Protocol
30 mg/kg; i.p.
In this assay, 20 g (±4 g) of female BALB/cAnNCrl (BALB/c) mice, 8 to 10 weeks old, are employed. 30 mice are given a single intraperitoneal (i.p.) dose of ciprofloxacin (Bay-09867) at a dose of 30 mg/kg. After receiving Ciprofloxacin for 1 hour, the mice (n = 3/time point/group) are culled at 1, 10, 20, or 30 minutes and at 1, 1.5, 2, 4, 8, or 12 hours later. After receiving DRCFI or CFI for 1 hour, 30 minutes, or 1 hour later, the mice are culled. Ciprofloxacin's short half-life and CFI's longer half-life are taken into consideration when selecting blood sampling locations. After death, blood and the lungs as an entire organ are taken for examination. The concentration of ciprofloxacin in the lung samples at one minute after administration is used to calculate the lung doses after CFI or DRCFI administration.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
A 250mg oral dose of ciprofloxacin reaches an average maximum concentration of 0.94mg/L in 0.81 hours with an average area under the curve of 1.013L/h\*kg. The FDA reports an oral bioavailability of 70-80% while other studies report it to be approximately 60%. An early review of ciprofloxacin reported an oral bioavailability of 64-85% but recommends 70% for all practical uses.
27% of an oral dose was recovered unmetabolized in urine compared to 46% of an intravenous dose. Collection of radiolabelled ciprofloxacin resulted in 45% recovery in urine and 62% recovery in feces.
Cirpofloxacin follws a 3 compartment distribution model with a central compartment volume of 0.161L/kg and a total volume of distribution of 2.00-3.04L/kg.
The average renal clearance after a 250mg oral dose is 5.08mL/min\*kg. Following a 100mg intravenous dose, the average total clearance is 9.62mL/min\*kg, average renal clearance is 4.42mL/min\*kg, and average non renal clearance is 5.21mL/min\*kg.
Based on population pharmacokinetics, bioavailability of ciprofloxacin oral suspension in children is approximately 60%. Following a single oral dose of 10 mg/kg of ciprofloxacin given as the oral suspension to children 4 months to 7 years of age, the mean peak plasma concentration was 2.4 ug/mL. There was no apparent age dependence and no increase in peak plasma concentrations following multiple doses.
When extended-release tablets containing ciprofloxacin hydrochloride (ProQuin XR) are administered with food, approximately 87% of the drug is gradually released from the tablet over a 6- hour period. When administered following a meal, peak plasma concentrations are attained approximately 4.5-7 hours after the dose. Bioavailability is substantially lower if ProQuin XR tablets are given while fasting. In healthy adults receiving ProQuin XR extended-release tablets in a dosage of 500 mg once daily given following a standardized meal, peak plasma concentrations at steady state (day 3) average 0.82 mcg/mL and are attained 6.1 hours after the dose. /Ciprofloxacin hydrochloride/
Following oral administration of extended-release tablets containing ciprofloxacin hydrochloride and base (Cipro XR), peak plasma concentrations of ciprofloxacin are attained within 1-4 hours. Cipro XR tablets contain approximately 35% of the dose within an immediate-release component; the remaining 65% of the dose is contained in a slow-release matrix. Oral administration of ciprofloxacin 500 mg daily as Cipro XR extended-release tablets or 250 mg twice daily as conventional tablets results in steady-state mean peak plasma concentrations of 1.59 or 1.14 ug/mL, respectively; however, the area under the concentration-time curve (AUC) is similar with both regimens. /Ciprofloxacin hydrochloride/
Peak serum concentrations of ciprofloxacin and AUCs of the drug are slightly higher in geriatric patients than in younger adults; this may occur because of increased bioavailability, reduced volume of distribution, and/or reduced renal clearance in these patients. Single-dose oral studies using ciprofloxacin conventional tablets and single- and multiple-dose IV studies indicate that, compared with younger adults, peak plasma concentrations are 16-40% higher, mean AUC is approximately 30% higher, and elimination half-life is prolonged approximately 20% in individuals older than 65 years of age. These differences can be at least partially attributed to decreased renal clearance in this age group and are not clinically important.
For more Absorption, Distribution and Excretion (Complete) data for CIPROFLOXACIN (18 total), please visit the HSDB record page.
Metabolism / Metabolites
Ciprofloxacin is primarily metabolized by CYP1A2. The primary metabolites oxociprofloxacin and sulociprofloxacin make up 3-8% of the total dose each. Ciprofloxacin is also converted to the minor metabolites desethylene ciprofloxacin and formylciprofloxacin. These 4 metabolites account for 15% of a total oral dose. There is a lack of available data on the enzymes and types of reactions involved in forming these metabolites.
The drug is partially metabolized in the liver by modification of the piperazinyl group to at least 4 metabolites. These metabolites, which have been identified as desethyleneciprofloxacin (M1), sulfociprofloxacin (M2), oxociprofloxacin (M3), and N-formylciprofloxacin (M4), have microbiologic activity that is less than that of the parent drug but may be similar to or greater than that of some other quinolones (e.g., M3 and M4 are comparable to norfloxacin for certain organisms).
Hepatic. Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose. The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin.
Route of Elimination: Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug.
Half Life: 4 hours
Biological Half-Life
The average half life following a 250mg oral dose was 4.71 hours and 3.65 hours following a 100mg intravenous dose. Generally the half life is reported as 4 hours.
The serum elimination half-life of ciprofloxacin in adults with normal renal function is 3-7 hours. Following IV administration in healthy adults, the distribution half-life of ciprofloxacin averages 0.18-0.37 hours and the elimination half-life averages 3-4.8 hours. The elimination half-life of the drug is slightly longer in geriatric adults than in younger adults, and ranges from 3.3-6.8 hours in adults 60-91 years of age with renal function normal for their age. Based on population pharmacokinetic analysis of pediatric patients with various infections, the predicted mean half-life of ciprofloxacin in children is approximately 4-5 hours. In patients with impaired renal function, serum concentrations of ciprofloxacin are higher and the half-life prolonged. In adults with creatinine clearances of 30 mL/minute or less, half-life of the drug ranges from 4.4-12.6 hours.
t1/2 for ciprofloxacin- normal: 4 (hr), anephric: 8.5 (hr) /from table/
Toxicity/Toxicokinetics
Toxicity Summary
The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.
Interactions
Serious and fatal reactions have been reported in patients receiving concurrent administration of ciprofloxacin and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Although similar serious adverse effects have been reported in patients receiving theophylline alone, the possibility that these reactions may be potentiated by ciprofloxacin cannot be eliminated. If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.
... The effects of aluminum hydroxide ... and calcium carbonate ... on the bioavailability of ciprofloxacin /was determined in/ ... a 3 way randomized, crossover study was concluded in 12 healthy male volunteers (ages 21-45 yr) that consisted of 3 treatments: 750 mg ciprofloxacin alone, 750 mg ciprofloxacin with 3.4 g calcium carbonate or 1.8 g aluminum hydroxide admin 5 min before ciprofloxacin. The relative bioavailability of ciprofloxacin was reduced to 60% and 15% of control values when given with calcium carbonate and aluminum hydroxide, respectively. ... It was concluded that antacids containing either aluminum or calcium should not be given concurrently with ciprofloxacin.
Ciprofloxacin, given to a patient successfully treated with methadone for more than 6 yrs, caused profound sedation, confusion, & respiratory depression. We suggest that this was caused by ciprofloxacin inhibition of CYP1A2 & CYP3A4 activity, 2 of the cytochrome p450 isozymes involved in the metab of methadone.
Synergism does not occur in vitro when ciprofloxacin is used in conjunction with vancomycin against Staphylococcus epidermidis, S. aureus (including oxacillin-resistant S. aureus), Corynebacterium, or Listeria monocytogenes.
For more Interactions (Complete) data for CIPROFLOXACIN (35 total), please visit the HSDB record page.
References

[1]. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63.

[2]. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16.

[3]. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.

[4]. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804.

Additional Infomation
Therapeutic Uses
Anti-Infective Agents; Nucleic Acid Synthesis Inhibitors
Ciprofloxacin (IV, conventional tablets, oral suspension) is used in adults for the treatment of bone and joint infections, including osteomyelitis, caused by susceptible E. cloacae, ... Ps. aeruginosa, or S. marcescens. ... /Included in US product label/
Ciprofloxacin (IV, conventional tablets, oral suspension) is used in adults for the treatment of bone and joint infections, including osteomyelitis, caused by susceptible E. aerogenes, ... E. coli, K. pneumoniae, M. morganii, P. mirabilis, ... . The drug also has been used in adults for the treatment of bone and joint infections caused by susceptible S. aureus, S. epidermidis, other coagulase-negative staphylococci, or Enterococcus faecalis (formerly S. faecalis), but other anti-infectives generally are preferred for these infections. Although resistance to ciprofloxacin has been reported in some strains of oxacillin-resistant S. aureus, oral ciprofloxacin may be a useful alternative to parenteral anti-infectives for the treatment of infections caused by susceptible oxacillin-resistant staphylococci. /NOT included in US product label/
Although only limited experience is available to date, ciprofloxacin is recommended by the American Heart Association (AHA) and Infectious Diseases Society of America (IDSA) as an alternative agent for the treatment of native or prosthetic valve endocarditis caused by fastidious gram-negative bacilli known as the HACEK group (Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Haemophilus aphrophilus, H. influenzae, H. parainfluenzae, H. paraphrophilus, Kingella denitrificans, K. kingae). /NOT included in US product label/
For more Therapeutic Uses (Complete) data for CIPROFLOXACIN (53 total), please visit the HSDB record page.
Drug Warnings
/BOXED WARNING/ WARNING: Fluoroquinolones, including Cipro, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
/BOXED WARNING/ WARNING: Fluoroquinolones, including Cipro, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid Cipro in patients with known history of myasthenia gravis.
In 4 corneal transplantation patients treated preoperatively with ciprofloxacin ophthalmic drops, microprecipitates associated with damaged corneal epithelium were noted in 2 patients. Another patient developed a large macroprecipitate in a corneal ulcer. All specimens were examined by electron microscopy & high-pressure liquid chromatography. The crystalline precipitates were pure ciprofloxacin. The macroprecipitate demonstrated a large zone of inhibition on agar plates seeded with a susceptible organism at 24 & 48 hr. It was bioactive & bioavailable in vitro.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should be administered as indicated.
For more Drug Warnings (Complete) data for CIPROFLOXACIN (41 total), please visit the HSDB record page.
Pharmacodynamics
Ciprofloxacin is a second generation fluoroquinolone that is active against many Gram negative and Gram positive bacteria. It produces its action through inhibition of bacterial DNA gyrase and topoisomerase IV. Ciprofloxacin binds to bacterial DNA gyrase with 100 times the affinity of mammalian DNA gyrase. There is no cross resistance between fluoroquinolones and other classes of antibiotics, so it may be of clinical value when other antibiotics are no longer effective. Ciprofloxain and its derivatives are also being investigated for its action against malaria, cancers, and AIDS.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C17H18FN3O3
Molecular Weight
331.34
Exact Mass
331.133
Elemental Analysis
C, 61.62; H, 5.48; F, 5.73; N, 12.68; O, 14.49
CAS #
85721-33-1
Related CAS #
86393-32-0;93107-08-5;97867-33-9
PubChem CID
2764
Appearance
White to off-white solid powder
Density
1.5±0.1 g/cm3
Boiling Point
581.8±50.0 °C at 760 mmHg
Melting Point
255-257°C
Flash Point
305.6±30.1 °C
Vapour Pressure
0.0±1.7 mmHg at 25°C
Index of Refraction
1.655
LogP
0.65
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
7
Rotatable Bond Count
3
Heavy Atom Count
24
Complexity
571
Defined Atom Stereocenter Count
0
SMILES
O=C(C1C(=O)C2C(=CC(N3CCNCC3)=C(C=2)F)N(C2CC2)C=1)O
InChi Key
MYSWGUAQZAJSOK-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
Chemical Name
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
Synonyms
Bay-09867; Baflox; Cetraxal; Ciprolin; Bay09867; Fimoflox; Bay 09867;Proflaxin; Spitacin
HS Tariff Code
2934.99.03.00
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.0180 mL 15.0902 mL 30.1805 mL
5 mM 0.6036 mL 3.0180 mL 6.0361 mL
10 mM 0.3018 mL 1.5090 mL 3.0180 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
CTID: NCT06709196
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-11-29
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
CTID: NCT06093191
Phase: Phase 4    Status: Recruiting
Date: 2024-10-16
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
CTID: NCT05462496
Phase: Phase 2    Status: Recruiting
Date: 2024-10-15
CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)
CTID: NCT05846399
Phase: Phase 4    Status: Recruiting
Date: 2024-10-01
Antibiotic Prophylaxis for Neurogenic Bladder Botox
CTID: NCT04791579
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-09-19
View More

Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
CTID: NCT03850379
Phase: Phase 2    Status: Completed
Date: 2024-09-19


Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
CTID: NCT05294588
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
CTID: NCT05804123
Phase: N/A    Status: Completed
Date: 2024-08-22
Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing
CTID: NCT06342830
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-20
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
CTID: NCT03511118
Phase:    Status: Recruiting
Date: 2024-07-24
Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
CTID: NCT04110340
Phase: Phase 3    Status: Recruiting
Date: 2024-06-17
Shigella Sonnei 53G Human Infection Study in Kenyan Adults
CTID: NCT05959616
Phase: Phase 1    Status: Not yet recruiting
Date: 2024-05-23
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
CTID: NCT04067011
Phase: Phase 2    Status: Completed
Date: 2024-03-21
Ciprofloxacin BioThrax Co-Administration Study
CTID: NCT01753115
Phase: Phase 2    Status: Completed
Date: 2024-03-18
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
CTID: NCT04948463
Phase: Phase 4    Status: Recruiting
Date: 2024-03-15
CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)
CTID: NCT04678869
Phase: N/A    Status: Recruiting
Date: 2024-03-08
Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients
CTID: NCT01785641
Phase: N/A    Status: Completed
Date: 2024-02-21
Antibiotic Prophylaxis for Bladder Botox
CTID: NCT04444440
Phase: Phase 4    Status: Recruiting
Date: 2024-02-08
Collaborative Urological Prosthetics Investigation Directive Research Group
CTID: NCT05100654
PhaseEarly Phase 1    Status: Active, not recruiting
Date: 2024-02-07
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
CTID: NCT02765256
Phase: Phase 2    Status: Completed
Date: 2024-02-06
Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin
CTID: NCT06234046
Phase: Phase 3    Status: Completed
Date: 2024-01-31
A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
CTID: NCT05844735
Phase: Phase 1    Status: Completed
Date: 2024-01-18
Antibiotic Treatment foLlowing Surgical drAinage of Perianal abScess; the ATLAS Trial
CTID: NCT05385887
Phase: N/A    Status: Recruiting
Date: 2023-11-13
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
CTID: NCT06126731
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2023-11-13
Pharmacokinetics of Ciprofloxacin in Pediatric Patients
CTID: NCT02598362
Phase: Phase 4    Status: Completed
Date: 2023-09-05
Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
CTID: NCT02620007
Phase: Phase 2    Status: Terminated
Date: 2023-08-23
Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
CTID: NCT04147260
Phase: Phase 1    Status: Completed
Date: 2023-07-17
Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting
CTID: NCT05916105
Phase:    Status: Completed
Date: 2023-06-23
Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
CTID: NCT03854929
Phase: Phase 4    Status: Completed
Date: 2023-06-07
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects
CTID: NCT05843708
Phase: Phase 1    Status: Recruiting
Date: 2023-06-05
Targeted AntiBiotics for Chronic Pulmonary Diseases
CTID: NCT03262142
Phase: Phase 4    Status: Terminated
Date: 2023-05-25
A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject
CTID: NCT05436678
Phase: Phase 1    Status: Completed
Date: 2023-02-08
A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects
CTID: NCT05232461
Phase: Phase 1    Status: Completed
Date: 2022-10-25
Bioequivalence Study of Ciprofloxacin in Healthy Adult Subjects Under Fasting Condition
CTID: NCT05532267
Phase: Phase 1    Status: Completed
Date: 2022-09-08
Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
CTID: NCT03012360
Phase: Phase 4    Status: Unknown status
Date: 2022-08-17
Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
CTID: NCT02773732
Phase: Phase 1/Phase 2    Status: Terminated
Date: 2022-08-05
Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma
CTID: NCT05431673
Phase: Phase 1    Status: Unknown status
Date: 2022-07-07
Modified Surface of PLGA Nanoparticles in Smart Hydrogel
CTID: NCT05442736
PhaseEarly Phase 1    Status: Completed
Date: 2022-07-05
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
CTID: NCT05398679
Phase: Phase 4    Status: Not yet recruiting
Date: 2022-06-01
S. Aureus Decolonization in HPN Patients.
CTID: NCT03173053
Phase: N/A    Status: Terminated
Date: 2022-05-31
Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
CTID: NCT03228108
Phase: Phase 4    Status: Completed
Date: 2022-05-10
Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.
CTID: NCT04698057
Phase: Phase 3    Status: Withdrawn
Date: 2022-03-31
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
CTID: NCT05286931
Phase: N/A    Status: Recruiting
Date: 2022-03-18
Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
CTID: NCT03862170
Phase: Phase 3    Status: Suspended
Date: 2022-03-17
Role of Prophylactic Postoperative Antibiotics in HoLEP
CTID: NCT05274672
Phase: Phase 4    Status: Unknown status
Date: 2022-03-11
Short-course Methenamine Hippurate for Prevention of Post-operative UTI
CTID: NCT02358993
Phase: N/A    Status: Completed
Date: 2022-02-25
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
CTID: NCT02790138
Phase: Phase 4    Status: Completed
Date: 2022-02-24
Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial
CTID: NCT00142272
Phase: Phase 3    Status: Completed
Date: 2022-02-11
Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
CTID: NCT03476317
Phase: Phase 2    Status: Completed
Date: 2022-02-09
Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
CTID: NCT04870138
Phase: Phase 1    Status: Completed
Date: 2021-12-02
Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan
CTID: NCT05106803
Phase:    Status: Completed
Date: 2021-11-04
Antibiotic Prophylaxis Before Shock Wave Lithotripsy
CTID: NCT03692715
Phase: Phase 4    Status: Recruiting
Date: 2021-10-18
Evaluation of Innovative Tools in Development of Antibiotics
CTID: NCT03177720
Phase: Phase 1    Status: Completed
Date: 2021-09-01
Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
CTID: NCT00654108
Phase: Phase 1    Status: Completed
Date: 2021-07-29
Longitudinal Study of the Human Intestinal Microbiome
CTID: NCT00832286
Phase: Phase 1    Status: Completed
Date: 2021-07-29
Clinical Efficacy of Crano-cure inTreatment of Urinary Tract Infection
CTID: NCT04575493
Phase: N/A    Status: Completed
Date: 2021-06-24
Experimental Human Infection With Neisseria Gonorrhoeae
CTID: NCT03840811
Phase: Phase 1    Status: Completed
Date: 2021-03-23
Targeted Retreatment of COPD Exacerbations
CTID: NCT02300220
Phase: Phase 3    Status: Completed
Date: 2021-03-08
Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy
CTID: NCT04374188
Phase: N/A    Status: Unknown status
Date: 2021-03-03
Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
CTID: NCT03354598
Phase: Phase 3    Status: Completed
Date: 2021-01-12
Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
CTID: NCT03357614
Phase: Phase 3    Status: Completed
Date: 2020-12-29
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
CTID: NCT03358576
Phase: Phase 3    Status: Completed
Date: 2020-12-01
A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)
CTID: NCT04636957
Phase: Phase 3    Status: Unknown status
Date: 2020-11-19
Impact of Formulation on Ciprofloxacin Oral Absorption
CTID: NCT00992329
Phase: Phase 1    Status: Completed
Date: 2020-11-06
Dose Ranging Study of OTO-201 in AOMT
CTID: NCT02719158
Phase: Phase 2    Status: Completed
Date: 2020-10-19
Phase 3 Study of OTO-201 in Acute Otitis Externa
CTID: NCT02801370
Phase: Phase 3    Status: Completed
Date: 2020-10-19
Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin
CTID: NCT04552431
Phase: Phase 2    Status: Completed
Date: 2020-09-18
Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae
CTID: NCT02961751
Phase: N/A    Status: Completed
Date: 2020-08-25
A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
CTID: NCT04523987
Phase: Phase 1    Status: Unknown status
Date: 2020-08-24
Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia
CTID: NCT02816112
Phase: Phase 4    Status: Completed
Date: 2020-05-27
Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC
CTID: NCT01265173
Phase: Phase 4    Status: Completed
Date: 2020-04-06
Antibiotic Prophylaxis in Laparoscopic Cholecystectomy
CTID: NCT01888822
Phase: Phase 4    Status: Terminated
Date: 2020-03-25
Antibiotic Prophylaxis With Routine Ureteral Stent Removal
CTID: NCT02944825
Phase: N/A    Status: Recruiting
Date: 2020-03-24
Special Drug Use Investigation of Ciproxan Injection in Pediatrics
CTID: NCT02555059
Phase:    Status: Completed
Date: 2020-02-28
Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation
CTID: NCT00791505
Phase: Phase 3    Status: Completed
Date: 2020-02-24
Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis
CTID: NCT02505581
Phase: Phase 4    Status: Completed
Date: 2020-01-14
Ciprofloxacin for Prevention of BK Infection
CTID: NCT01789203
Phase: Phase 4    Status: Completed
Date: 2019-11-13
Antibiotics and Hydroxychloroquine in Crohn's
CTID: NCT01783106
Phase: Phase 2    Status: Completed
Date: 2019-10-31
Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
CTID: NCT03366207
Phase: Phase 4    Status: Completed
Date: 2019-09-06
Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
CTID: NCT03431675
Phase: Phase 4    Status: Withdrawn
Date: 2019-08-14
Ciprofloxacin Plus Metronidazole Vs Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess
CTID: NCT03969758
Phase: Phase 3    Status: Unknown status
Date: 2019-07-22
BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
CTID: NCT02068846
Phase: Phase 3    Status: Completed
Date: 2019-07-11
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
CTID: NCT01659866
Phase: Phase 4    Status: Completed
Date: 2019-06-25
Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
CTID: NCT01505634
Phase: Phase 2    Status: Completed
Date: 2019-05-24
PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis
CTID: NCT03027635
Phase: N/A    Status: Terminated
Date: 2019-05-20
Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole
CTID: NCT02734732
Phase: Phase 2    Status: Unknown status
Date: 2019-05-15
Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
CTID: NCT01952444
Phase: Phase 1    Status: Completed
Date: 2019-04-16
Antibiotic Prophylaxis for Endoscopic Ultrasound Guided Fine Needle Aspiration of Pancreatic Cystic Lesions
CTID: NCT02261896
Phase: Phase 4    Status: Completed
Date: 2019-04-12
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
CTID: NCT01208922
Phase: Phase 3    Status: Completed
Date: 2019-02-27
Otiprio Versus Ciprodex Tympanostomy Tube Outcomes
CTID: NCT03347461
Phase: Phase 4    Status: Withdrawn
Date: 2018-09-14
Antibiotics for Klebsiella Liver Abscess Study
CTID: NCT01723150
Phase: Phase 4    Status: Completed
Date: 2018-08-27
Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy
CTID: NCT02252978
Phase: Phase 2    Status: Withdrawn
Date: 2018-07-05
Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases
CTID: NCT00137787
Phase: Phase 3    Status: Completed
Date: 2018-06-26
Efficiency of Triple Antibiotic Paste, Ciprofloxacin/Propolis, Ciprofloxacin/Metronidazole, Propolis/Metronidazole Combinations on Revascularization Process of Immature Necrotic Maxillary Incisors of Patients 8-18 Years Old.
CTID: NCT03533231
Phase: Phase 4    Status: Completed
Date: 2018-05-30
Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma
CTID: NCT03326050
PhaseEarly Phase 1    Status: Unknown status
Date: 2018-02-13
Ciprofloxacin for the Prevention of Meningococcal Meningitis
CTID: NCT02724046
Phase: Phase 4    Status: Completed
Date: 2018-02-08
Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
CTID: NCT01803191
Phase: Phase 4    Status: Completed
Date: 2017-12-13
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
CTID: NCT00688272
Phase: Phase 1    Status: Completed
Date: 2017-11-17
Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics
CTID: NCT02223338
Phase: N/A    Status: Completed
Date: 2017-11-07
REaCT Integrated Consent Model to Compare Two Standard of Care Regimens
CTID: NCT02173262
Phase: Phase 4    Status: Completed
Date: 2017-11-06
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
CTID: NCT00590785
Phase: Phase 3    Status: Completed
Date: 2017-08-25
Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients
CTID: NCT02011841
Phase: Phase 3    Status: Withdrawn
Date: 2017-04-25
Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy
CTID: NCT02247960
Phase: N/A    Status: Terminated
Date: 2017-04-17
A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy
CTID: NCT02423759
Phase: Phase 4    Status: Completed
Date: 2017-04-04
Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects
CTID: NCT02118909
Phase: Phase 1    Status: Completed
Date: 2017-02-23
Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis
CTID: NCT02326103
PhaseEarly Phase 1    Status: Completed
Date: 2017-01-19
Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention
CTID: NCT01542801
Phase: Phase 4    Status: Completed
Date: 2016-12-28
Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy
CTID: NCT00214331
Phase:    Status: Completed
Date: 2016-10-27
Cerebral Antibiotics Distribution After Acute Brain Injury
CTID: NCT01059890
Phase: Phase 1    Status: Completed
Date: 2016-10-11
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
CTID: NCT01649635
Phase: Phase 4    Status: Completed
Date: 2016-07-06
A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration
CTID: NCT01929460
Phase: N/A    Status: Completed
Date: 2016-02-15
Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)
CTID: NCT01873690
Phase: Phase 3    Status: Terminated
Date: 2016-02-08
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory
A Multicentre Randomised Control Trial Assessing the Efficacy of Antimicrobial Prophylaxis for Extracorporeal Shock Wave Lithotripsy on reducing Urinary Tract Infections
CTID: null
Phase: Phase 4    Status: Completed
Date: 2021-11-26
A multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients: efficacy and microbiologic safety.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2021-11-11
Prospective randomized controlled study of two antibiotic treatment times (3 versus 6 weeks) of diabetic foot osteomyelitis
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2021-07-22
Pathophysiological mechanisms in the development of anal fistula. Oral antibiotics after anal abscess drainage to diminish perianal Fistula Formation: a multicenter, randomized, observer-blind, placebo-controlled clinical trial.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2021-05-04
Pivmecillinam with Amoxicillin/clavulanic acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales.
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2021-02-16
Amoxicillin-clavulanate alone or in combination with Ciprofloxacin in Low-Risk Febrile Neutropenic adult Patients:
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2020-09-15
Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study.
CTID: null
Phase: Phase 4    Status: Ongoing, Prematurely Ended
Date: 2020-04-08
ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS: AIR.
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2020-04-03
Revised dosing recommendations of ciprofloxacin for patients with impaired renal function: a bioequivalence study.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2020-03-10
ABSORB 2:An exploratie study determining the oral antibiotic drug absorption in patients with short bowel syndrome.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2020-02-25
Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2020-02-11
Exposure to orally administered antibiotics during the initial phase of infection in non-critically ill, febrile patients
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2019-07-03
A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection
CTID: null
Phase: Phase 2, Phase 3    Status: Restarted, Completed
Date: 2019-06-26
Impact on the intestinal microbiota during antibiotic treatment
CTID: null
Phase: Phase 2    Status: Completed
Date: 2019-05-17
Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2019-04-29
Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2019-01-14
A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults
CTID: null
Phase: Phase 3    Status: Temporarily Halted, Prematurely Ended, Completed
Date: 2018-10-17
Pharmacokinetics of different antibiotics in cerebrospinal fluid in children with malignant brain tumors – a pilot study
CTID: null
Phase: Phase 1    Status: Ongoing
Date: 2018-09-27
Optimized treatment for uncomplicated acute appendicitis - active observation with or without antibiotic treatment. A phase IV consecutive clinical treatment trial.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2018-07-30
Immediate oral, immediate topical or delayed oral antibiotics for acute otitis media with discharge (the Runny Ear STudy: REST)
CTID: null
Phase: Phase 4    Status: Completed
Date: 2018-05-23
The effect of rectal swab culture-guided antimicrobial prophylaxis in men undergoing prostate biopsy on infectious complications and cost of care: A randomized controlled trial in the Netherlands.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2018-02-06
A multicenter, open-label, randomized, active-controlled, parallel group, pivotal study to investigate the efficacy, safety and tolerability, and pharmacokinetics of murepavadin combined with one anti-pseudomonal antibiotic versus two anti-pseudomonal antibiotics in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa.
CTID: null
Phase: Phase 3    Status: Ongoing, Prematurely Ended
Date: 2018-01-29
Right Dose, Right Now: Randomized Clinical Trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2018-01-11
Acute uncomplicated diverticulitis: prospective, controlled, randomized, multicenter clinical trial of non-antibiotic outpatient treatment (TASDA trial).
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-12-14
Fosfomycin vs Ciprofloxacin for transrectal biopsy - a randomized
CTID: null
Phase: Phase 2    Status: Completed
Date: 2017-05-16
Target-ABC (Targeted AntiBiotics for Chronic pulmonary disease):
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2017-01-14
Placebo-kontrollierte, multizentrische, randomisierte, doppelblinde Phase III-Studie zur Verbesserung der gastrointestinalen Verträglichkeit einer per-oralen Antibiotikatherapie durch add-on-Gabe von Lactobacillus rhamnosus GG (InfectoDiarrstop® LGG® Mono Kapseln) bezogen auf die Häufigkeit einer AAD bei Kindern unter 2 Jahren
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2016-11-17
Combined Effect of CFTR Modifiers and Intensive Antibiotic Treatment
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-08-15
Antibiotic prophylaxis before extracorporeal shock wave lithotripsy (APPEAL)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2016-06-28
Individualized dosing of aminoglycosides, quinolones and glycopeptide antibiotics in (morbidly) obese patients
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-05-18
Randomized, multicenter, open, phase III, controlled clinical trial, to demonstrate the non-inferiority of reduced antibiotic treatment directed against the treatment of a broad spectrum betalactam antipseudomonal in treating patients with bacteremia spectrum Enterobacteriaceae
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-03-18
Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2015-03-16
Pharmacokinetics of ciprofloxacine in pediatric patients, a pilot study – SAFE PEDRUG.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-03-10
Antibiotic prophylaxis oral vs parenteral + parenteral in colonic surgery: a prospective, randomized, multicenter clinical trial.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-01-19
Development of a tool for adapting dosage of fluoroquinolones by using a population pharmacokinetic model
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2014-12-12
Multicenter, randomized and double-blinded clinical trial on the use of antibiotic prophylaxis for EUS guided FNA of pancreatic cystic lesions
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-08-18
MEROPENEM and CIPROFLOXACIN DOSING IN THE CRITICALLY ILL PATIENT WITH SEPTIC SHOCK –
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-07-25
Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic f e.querySelector("font strong").innerText = 'View More' } else if(up_display === 'none' || up_display === '') { icon_angle_down.style.display = 'none';

Biological Data
  • Postexposure prophylaxis. Shown is the survival of mice infected with Y. pestis following treatment with omadacycline, doxycycline, or ciprofloxacin (all given i.p.). n = 10 for all groups. Antimicrob Agents Chemother . 2017 Apr 24;61(5):e02434-16.
  • Lung and plasma concentration-time profile of ciprofloxacin administered as intraperitoneal (IP) ciprofloxacin or aerosolized CFI or DRCFI to BALB/c mice. Front Microbiol. 2017 Feb 6;8:91.
  • Therapeutic efficacy of intraperitoneally delivered ciprofloxacin, aerosolized CFI or DRCFI prophylaxis in a mouse model of inhalational Yersinia pestis infection. Front Microbiol. 2017 Feb 6;8:91.
  • The effect of ciprofloxacin, CFI or DRCFI prophylaxis on bacterial burden in a mouse model of inhalational Y. pestis infection. Front Microbiol. 2017 Feb 6;8:91.
  • Increased Susceptibility to Challenge-Induced Aortic Aneurysm and Dissection (AAD) Formation in Mice That Received Ciprofloxacin. JAMA Surg . 2018 Sep 1;153(9):e181804.
  • Similar Adverse Effects of Ciprofloxacin on Aortic Aneurysm and Dissection (AAD) Development in Male and Female Mice. JAMA Surg . 2018 Sep 1;153(9):e181804.
  • Decreased Lysyl Oxidase (LOX) Protein Expression and Increased Matrix Metalloproteinase (MMP) Expression and Activity in the Aortic Wall of Challenged Mice That Received Ciprofloxacin. JAMA Surg . 2018 Sep 1;153(9):e181804.
Contact Us